gastric cancer
Conditions
Interventions
Conventional Chemotherapy group:None
Metronomic Chemotherapy group:None
Metronomic Chemotherapy Combined with Immunotherapy group:None
Sponsors
Huashan Hospital Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old; 2. Histopathologically confirmed unresectable locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GEJ); 3. Received and completed one of the following first-line or subsequent systemic therapies at our hospital between January 2015 and January 2025: Monotherapy 1: Conventional-dose chemotherapy alone Combination therapy 1: Conventional-dose chemotherapy combined with immunotherapy Monotherapy 2: Metronomic chemotherapy alone Combination therapy 2: Metronomic chemotherapy combined with immunotherapy 4. Completed at least one full treatment cycle; 5. Complete baseline imaging data (CT/MRI/contrast-enhanced CT) available; 6. Complete follow-up data available, or status at last follow-up and survival outcomes can be confirmed.
Exclusion criteria
Exclusion criteria: 1. Received systemic treatment with traditional Chinese medicines (TCMs) having anti-tumor indications or immunomodulatory drugs (including Thymopeptides, Interferon, Interleukin) within 2 weeks prior to treatment initiation, excluding local use for pleural effusion control; 2. Participated in an interventional clinical trial during treatment, or received other investigational drugs or used investigational devices within 4 weeks prior to the first dose; 3. Severe deficiency of key baseline data (e.g., pathological type, stage, initial treatment regimen) or survival data; 4. Diagnosed with another malignant disease (excluding radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ) within 5 years prior to the first dose; 5. Previous administration of anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or drugs targeting other stimulatory or co-inhibitory T-cell receptors (including but not limited to CTLA-4, OX-40, CD137, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Surivival;Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactZhongguang Luo
Huashan Hospital Fudan University
Outcome results
None listed